"In precision oncology, treatment selection is not only about identifying what may work but also understanding factors that may affect how safely a patient can receive therapy," said Caris President David Spetzler, MS, PhD, MBA. "During Colorectal Cancer Awareness Month, it is important to recognize that DPYD testing can provide clinically meaningful information before treatment begins, helping clinicians make more informed decisions for patients who may be candidates for fluoropyrimidine-based therapy." As ...

Core Insights - Caris Life Sciences has launched a proprietary Caris AI Insights signature for pancreatic cancer, aimed at guiding first-line therapy selection and treatment de-escalation [1] - The Caris Molecular Tumor Board Report provides tumor profiling without additional tissue sampling, enhancing precision oncology through multimodal real-world datasets [1] - The new AI Insights utilize Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to offer actionable insights for clinicians, particularly for pancreatic ductal adenocarcinoma (PDAC) [1] Company Developments - Caris Life Sciences integrates over 550,000 patient datasets to develop next-generation multimodal models for biomarker discovery and personalized cancer treatments [1] - The PDAC signature categorizes patients into standard or high risk and recommends treatment options based on molecular patterns, addressing the lack of actionable biomarker guidance in current therapies [1] - The company received FDA approval in November 2024 for MI Cancer Seek, the first tissue-based assay combining WES and WTS with FDA-approved companion diagnostic indications [1] Future Outlook - A future publication is anticipated to reveal how Caris AI Insights can identify patients suitable for treatment de-escalation and those who may benefit from more intensive therapies [1]